Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australian Progen CEO Says Oncology Pipeline Advances Despite Troubles

This article was originally published in PharmAsia News

Executive Summary

Australia's Progen Pharmaceuticals says it is staying on track and pushing its anti-cancer drugs through its pipeline despite several upheavals that have plagued it for the past six months. CEO Justus Homburg presented an upbeat view of the company's prospects, such as its metastatic melanoma drug now about to enter Phase II trials. Progen also says its small-molecule heparanese inhibitor discovery program also is getting encouraging results. Progen has been under attack by two separate groups of shareholders, including another cancer drug developer with stock, Cytopia, which also helped derail a Progen merger with Avexa. (Click here for more

You may also be interested in...

Keeping Track: Tauvid, Oriahnn, Artesunate Clear US FDA, Along With Trio Of Pediatric Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Goldman Sachs Gains 2 Board Seats With Burst Subscription Oral Care Investment

Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.

Health And Wellness Trademark Review 26 May, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts